A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. - Wikidata - wikimedia - TriplyDB

A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.

A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.

http://www.wikidata.org/entity/Q37286911

about

Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Daptomycin for the treatment of major gram-positive infections after cardiac surgery.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Daptomycin and Its Immunomodulatory Effect: Consequences for Antibiotic Treatment of Methicillin-Resistant Staphylococcus aureus Wound Infections after Heart Surgery.Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British He When sepsis persists: a review of MRSA bacteraemia salvage therapy.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin.Differences in Method-Specific Vancomycin MICs and Induced Daptomycin Resistance in an Infective Endocarditis Patient.Study on daptomycin use and implementation of an antimicrobial stewardship program.The Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the Eur What's New in the Treatment of Enterococcal Endocarditis?Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Infective endocarditis.Daptomycin versus teicoplanin for bloodstream infection due to methicillin-resistant Staphylococcus aureus with a high teicoplanin minimal inhibitory concentration ≥1.5 mg/L: a propensity score-based analysis

P2860

Q26851754-B7C1738A-AEAE-4B9F-84C8-83792C8346B1 Q34058360-704A4139-B259-406F-BA8D-90B0F1EBE66D Q34478074-A60DF2BE-97AC-45CA-9595-05DA96612DB2 Q35385108-2C773B31-0903-4072-B846-24D46387CFA0 Q35802607-A410869F-EA51-4216-868C-779710019351 Q35819409-0F423A3B-756E-4BEC-A758-A64AA6D6767C Q35848781-F7881133-691C-4AE5-B749-8B6693EBE04F Q35974360-2C3CDD63-39C1-42D3-BD1D-4AA850DFA70F Q36683458-FBDFD30E-AC2A-4724-A92C-D7261CAB4CF1 Q36686882-B56C807B-29ED-42B2-9C7A-E8DEF9056B86 Q37150644-D9E2303E-DE38-47DE-84AB-ED39ED98EDF8 Q37287661-1F622647-F5CB-48C6-B784-22CE452D501B Q38198019-564366F8-1C11-490E-AB9E-C3FA66C6D116 Q38263821-AA8FFF44-6337-4B63-9F8D-E7E00B041A9D Q38632488-DC32F15A-1DEF-46F5-9F19-719171F34790 Q38895642-E3C960D6-4C9A-4D12-98A3-DBC0A2F32B0C Q38990504-86889136-24FF-49AC-A992-014C9BFF1014 Q39488590-D6905BA7-73EA-41E4-B581-602F4BD323F6 Q40083539-C9F1AD91-05A8-4C55-9FFD-A6768939829B Q40722135-E76354E5-C8E0-4D87-9684-DB0131D42E0A Q40728255-54844D30-5B19-4F1A-AF2C-056F5ED70863 Q40764649-1549B2BE-4DD9-4C45-8BFF-417DCE4247A5 Q40837656-CF7531B6-3A26-4C5E-A6AF-8EFBCCF04232 Q41026009-25ADCF89-69C4-4A04-A13C-12C06C37B405 Q41368979-DCDB6112-D170-43BB-A6B6-653CBEF46C55 Q41644243-7D81DA86-90F6-4D6D-B3F0-619E07A8D6AA Q47318913-5CC65646-2AD3-4CB3-B3FF-DCB1ABF109A4 Q52943386-577AF154-FDF6-4838-8371-C3EAED5F3E1B Q59135465-C40490BB-0B9F-4F79-ADC4-1C1B8588B4DA

P2860

A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.

http://www.wikidata.org/entity/Q37286911

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A multicentre evaluation of th ...... ent of infective endocarditis.

@en

A multicentre evaluation of th ...... ent of infective endocarditis.

@nl

type

label

A multicentre evaluation of th ...... ent of infective endocarditis.

@en

A multicentre evaluation of th ...... ent of infective endocarditis.

@nl

prefLabel

A multicentre evaluation of th ...... ent of infective endocarditis.

@en

A multicentre evaluation of th ...... ent of infective endocarditis.

@nl

P1433

Q37286911-4947159B-A35B-4602-B106-EA6293EB7618

P1476

Q37286911-AFF55863-ECB3-4F4F-9395-809A4028AC67

P2093

Q37286911-10E673F7-79C1-42F7-A614-8FD30AC504E0

Q37286911-265A8A88-8DF5-4BD3-8217-A59492572C17

Q37286911-27CDB6EE-D69C-4DAD-9786-CBC82F8B7867

Q37286911-43668C48-6253-46FD-AC9B-4709E4F59C0E

Q37286911-70C26650-24D4-4388-98BD-19C76A1CD72D

Q37286911-B011DE26-210A-46CE-9BFC-DC3A09AE6A78

Q37286911-BCBA3EA5-B622-476D-834C-AA3A13715128

Q37286911-D8DF1DA7-406B-46B0-B55A-288301CC69BF

Q37286911-E1C5EF5D-90B8-41C6-BF97-01B33408E956

Q37286911-EE1BB5BF-EC5F-4049-A312-B15E4860B9C0

P2860

Q37286911-026A9FF6-750E-43CB-9C90-96B785DE3152

Q37286911-0A916D74-23F3-4473-B4B6-8E02BE551F1F

Q37286911-1CDC3645-D77F-4681-94B5-DE8D8813ECA5

Q37286911-2642B116-4E66-4220-8A96-1043DC595A54

Q37286911-2C120975-986A-4BAA-BCF0-15BFC141980C

Q37286911-389E7C40-1AE9-472E-B153-B676259E6F60

Q37286911-4EF6EC93-3459-46D0-B262-D44971D62411

Q37286911-50230E64-17BB-40E6-93A6-0D3250C432E3

Q37286911-52E7C859-B45F-4D8F-BE81-EF3CFFB165C5

Q37286911-6160F571-DFB1-4823-B4BF-73836937A1EE

P304

Q37286911-A49B4E1B-08D0-40A3-9FEB-D1230169A211

P31

Q37286911-4034A3D9-17ED-4299-955B-A54E27A12B51

P356

Q37286911-E5653778-71CB-471E-A8F3-F271EA00F0B4

P407

Q37286911-FA82D6C7-4039-406B-997B-5EBF529A2B15

P433

Q37286911-8CB6AC15-8932-449A-B6C5-10D5C5A883AD

P478

Q37286911-5AF16CC5-2C2B-41AE-AC47-0D07DA52E2CA

P577

Q37286911-9DAEEEB6-3B5C-42F8-BBB1-C33F95010658

P698

Q37286911-85BC8604-675C-4DA5-8599-5EEC7D2131CB

P921

Q37286911-02A652A9-4412-40E8-8ECD-FB0A7D3D4A41

P932

Q37286911-948D67E1-328D-4C5D-818C-E11977AAE111

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

A multicentre evaluation of th ...... ent of infective endocarditis.

@en

P2093

Anthony M Casapao

http://www.w3.org/2001/XMLSchema#string

Christopher W Crank

http://www.w3.org/2001/XMLSchema#string

Donald P Levine

http://www.w3.org/2001/XMLSchema#string

George Sakoulas

http://www.w3.org/2001/XMLSchema#string

Jing J Zhao

http://www.w3.org/2001/XMLSchema#string

John Segreti

http://www.w3.org/2001/XMLSchema#string

Michael J Rybak

http://www.w3.org/2001/XMLSchema#string

Ravina Kullar

http://www.w3.org/2001/XMLSchema#string

Sara E Cosgrove

http://www.w3.org/2001/XMLSchema#string

Susan L Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Daptomycin dose-effect relationship against resistant gram-positive organisms

Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.

P304

2921-2926

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKT294

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23928022

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3820108

http://www.w3.org/2001/XMLSchema#string